Survodutide is an investigational dual GLP-1/glucagon receptor agonist under active evaluation for metabolic dysfunction-associated steatohepatitis (MASH).
Read more Survodutide in MASH Research: Clinical Evidence and Hepatic Mechanisms
Retatrutide in liver disease research shows remarkable reductions in hepatic fat. Clinical trials reveal triple GIP/GLP-1/glucagon receptor agonism resolve
Read more Retatrutide in Liver Disease Research: Evidence for Hepatic Fat Reduction
While approved for diabetes and weight management, tirzepatide is under active investigation for broader cardiometabolic indications. Emerging clinical tri
Read more Tirzepatide in Emerging Indications: Liver, Kidney, and Cardiovascular Research
An evidence-based scientific review of survodutide (BI 456906), exploring its dual GLP-1 and glucagon receptor agonism, Phase 2 trial results in MASH and o
Read more Survodutide: Mechanism of Action and Clinical Trial Evidence